Should Pfizer Buy Eli Lilly?

Pfizer failed to capture AstraZeneca, but could Eli Lilly be a better target?

Jun 13, 2014 at 5:00PM

On the heels of its failed courtship of AstraZeneca (NYSE:AZN), Pfizer (NYSE:PFE) may want to turn its attention to Eli Lilly (NYSE:LLY) -- another drugmaker with proven diabetes treatments and promising oncology drugs.

Pfizer was ready to pay $118 billion for AstraZeneca, but it might win Lilly for less.

PFE Chart

PFE data by YCharts.

What Pfizer wants
AstraZeneca's attractiveness stemmed from its established diabetes franchise and its potential new cancer drugs.

In December, AstraZeneca acquired the half of its diabetes partnership it didn't own from Bristol-Myers Squibb, agreeing to pay nearly $2.7 billion up front and future milestone and royalty payments in exchange for full control of Onglyza, Atacand, Byetta, and Bydureon.

In addition to the $1 billion a year diabetes business, Pfizer was also intrigued by AstraZeneca's oncology portfolio.

AstraZeneca already markets five oncology drugs that generate a combined $750 million in quarterly sales. Those sales could climb substantially if AstraZeneca's oncology research results in approvals. The company's cancer drug pipeline includes ovarian cancer treatment olaparib and PD-L1 drug MEDI4736, two products that if approved may eventually combine to generate billions of dollars a year in peak sales.

What Lilly delivers
LIke AstraZeneca, Eli Lilly boasts a proven stable of diabetes drugs that includes top-selling insulin Humalog, which posted sales of more than $2.6 billion last year, up 9% from 2012. Lilly also markets the diabetes drug Humulin, which generated $1.3 billion in sales during 2013.

Lilly's pipeline also includes additional promising diabetes drugs such as dulaglutide and empagliflozin.

Dulaglutide is a GLP-1 diabetes drug that is being reviewed for approval by the FDA. If approved, dulaglutide will face off against Novo Nordisk's blockbuster Victoza and AstraZeneca's top-selling Bydureon and Byetta. Empagliflozin is a SGLT-2-targeting diabetes drug that will likely be resubmitted for approval soon given that FDA concerns over Lilly's partner Boehringer's manufacturing plant have been addressed. If approved, empagliflozin would compete for share against Johnson & Johnson's Invokana and AstraZeneca's Farxiga.


Source: Eli Lilly.

Lilly also markets proven cancer drugs such as Alimta, a lung cancer therapy that posted sales of $2.7 billion in 2013, up 4% from 2012. And Lilly's drug pipeline just notched FDA approval of gastric cancer drug Cyramza, which may also have potential in lung cancer. Lilly also has necitumumab in phase 3 trials for non-small cell lung cancer and 14 ongoing phase 2 cancer programs.

In addition, if Pfizer were to acquire Lilly it would get its hands on the blockbuster osteoporosis drug Forteo, ADHD drug Strattera, and cardiovascular drug Effient. Strattera and Effient both posted double-digit sales growth last year, respectively climbing to $709 million and $509 million. Pfizer would also gain Lilly drugs in phase 3 trials for rheumatoid arthritis, psoriasis, lupus, and pain. Of course, Lilly wouldn't give Pfizer the benefit of the tax inversion that Astra would have -- something which many argued was a big part of the premium Pfizer was willing to pay. 

Fool-worthy final thoughts
AstraZeneca's goal of $45 billion a year in annual sales, 75% more than it's generating today, would go a long way to justifying Pfizer's nine-figure offer price. However, hitting that sales target requires a lot of things to go right, which is particularly difficult in oncology, where more than 90% of drugs in trials fail to reach the market.

Pfizer was willing to pay 4.7 times AstraZeneca's current sales to capture that potential opportunity (and risk). Since Lilly's market cap stands at $63 billion, Pfizer could potentially buy the company for less than it offered AstraZeneca (which has a market cap of over $90 billion), but that doesn't mean it will happen. Pfizer may simply not be interested in buying Lilly -- it doesn't have AstraZeneca's tax benefit, and the pipeline is materially different. And Lilly may be just as reticent to sell as AstraZeneca, but Pfizer won't know if it doesn't ask.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need to Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients do not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers